Immuno-oncology Services

Protagen specializes in supporting the pharma and biotech industries in their quest to develop effective immunotherapies, via collaborative projects with its strategic partners. At the forefront of immuno-profiling, and the discovery of novel autoantibodies as effective biomarkers for immuno-oncology, Protagen is helping to overcome the barriers to successful cancer treatment.

Using its proprietary biomarker identification platform (SeroTag®), and with a pipeline of stratification arrays based on biomarker panels (NavigAID) to screen patient serum specimens currently under development, Protagen is able to detect novel autoantibody signatures to provide:

  • Improved response prediction and patient monitoring via autoantibody profiling

  • The early detection of immune-related adverse events (irAEs)

Download our new whitepaper to learn more about how biomarker discovery can enhance cancer immunotherapy development.


Immunotherapies hold great promise for treating cancer, but only work effectively on a subset of patients. Protagen supports effective immunotherapy development via its SeroTag® platform to improve therapeutic outcomes and detect adverse side effects (irAEs)

NavigAID for immuno-oncology

NavigAID is already showing promise in the stratification of autoimmune diseases to improve treatment responses, and Protagen is currently assessing its application in defining cancer patient subgroups to enhance the effectiveness of immunotherapies and predict as well as monitor irAEs.

SeroTag® platform

Protagen is uniquely positioned via its SeroTag® platform to combine its large library of human proteins with the high-throughput identification of immuno-oncology biomarkers, to develop more effective immunotherapies.